Publications by authors named "Rebecca Garris"

Claim this Profile
M
Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia.
Nicholas J Short, Hagop Kantarjian, Nitin Jain, Tapan M Kadia, Jayastu Senapati, Rebecca Garris

Blood Adv· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy-Based Regimens.
Hannah Goulart, Elias Jabbour, Nicholas Short, Nitin Jain, Ghayas Issa, Rebecca Garris

Am J Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia.
Roberta S Azevedo, Elias Jabbour, Hagop M Kantarjian, Sravanthi Lavu, Sanam Loghavi, Rebecca Garris

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL.
Nicholas J Short, Elias Jabbour, Walid Macaron, Nitin Jain, Fadi G Haddad, Rebecca Garris

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tyrosine Kinase Inhibitors During Frontline Therapy in Adults With Acute Lymphoblastic Leukemia With ABL-class Rearrangements.
Julie Braish, Hagop Kantarjian, Nicholas J Short, Guilin Tang, Naval Daver, Rebecca Garris

Clin Lymphoma Myeloma Leuk· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab.
Nicholas J Short, Hagop Kantarjian, Ken Furudate, Nitin Jain, Farhad Ravandi, Rebecca Garris

J Hematol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
Hagop Kantarjian, Nicholas J Short, Nitin Jain, Fadi G Haddad, Tapan Kadia, Rebecca Garris

Am J Hematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Eitan Kugler, Hagop Kantarjian, Elias Jabbour, Niranjan Khaire, Nicholas J Short, Rebecca Garris

Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL.
Hagop Kantarjian, Nicholas J Short, Fadi G Haddad, Nitin Jain, Xuelin Huang, Rebecca Garris

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma.
Farhad Ravandi, Jayastu Senapati, Nitin Jain, Nicholas J Short, Tapan Kadia, Rebecca Garris

Leukemia· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.
Wei-Ying Jen, Elias Jabbour, Nicholas J Short, Ghayas C Issa, Fadi G Haddad, Rebecca Garris

Am J Hematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin.
Jayastu Senapati, Elias Jabbour, Nicholas J Short, Nitin Jain, Fadi Haddad, Rebecca Garris

Blood Cancer J· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Yaqi Zhao, Nicholas J Short, Hagop M Kantarjian, Ti-Cheng Chang, Pankaj S Ghate, Rebecca S Garris

Blood· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
Nicholas J Short, Elias Jabbour, Lewis F Nasr, Nitin Jain, Fadi G Haddad, Rebecca Garris

Am J Hematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia.
Nicholas J Short, Elias Jabbour, Trevor Jamison, Shilpa Paul, Branko Cuglievan, Rebecca Garris

Clin Lymphoma Myeloma Leuk· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Elias Jabbour, Fadi G Haddad, Nicholas J Short, Jayastu Senapati, Nitin Jain, Rebecca S Garris

Blood· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
Nicholas J Short, Elias Jabbour, Nitin Jain, Jayastu Senapati, Lewis Nasr, Rebecca Garris

Blood Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Yaqi Zhao, Nicholas J Short, Hagop M Kantarjian, Ti-Cheng Chang, Pankaj S Ghate, Rebecca S Garris

medRxiv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Nicholas J Short, Elias Jabbour, Walid Macaron, Farhad Ravandi, Nitin Jain, Rebecca Garris

Am J Hematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
Elias Jabbour, Nicholas J Short, Jayastu Senapati, Nitin Jain, Xuelin Huang, Rebecca Garris

Lancet Haematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.
Hagop Kantarjian, Fadi G Haddad, Nitin Jain, Koji Sasaki, Nicholas J Short, Rebecca Garris

J Hematol Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
Hagop Kantarjian, Nicholas J Short, Nitin Jain, Koji Sasaki, Xuelin Huang, Rebecca Garris

Am J Hematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Elias Jabbour, Nicholas J Short, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Rebecca Garris

Lancet Haematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.
Elias Jabbour, Nicholas J Short, Nitin Jain, Philip A Thompson, Tapan M Kadia, Rebecca Garris

Lancet Haematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10 and higher.
Elias J Jabbour, Nicholas J Short, Nitin Jain, Nadya Jammal, Jeffrey Jorgensen, Rebecca Garris

Am J Hematol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis